Alexander Marr

Dr. Alexander Marr


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
KKKilannin Krysiak
Kilannin Krysiak
ADArpad M. Danos
Arpad M. Danos
SKSusanna Kiwala
Susanna Kiwala
JMJoshua F. McMichael
Joshua F. McMichael
ACAdam C. Coffman
Adam C. Coffman
MGMalachi Griffith
Malachi Griffith

5 November 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
BGBritten K. Gordon
Britten K. Gordon
EMElizabeth M. Muhowski
Elizabeth M. Muhowski
JSJyotsana Singh
Jyotsana Singh
JRJanani Ravikrishnan
Janani Ravikrishnan
APArnau Peris-Cuesta
Arnau Peris-Cuesta
JWJennifer A. Woyach
Jennifer A. Woyach
Inhibition of the tyrosine kinase BTK is a major therapeutic strategy for treating B-cell malignancies, including chronic lymphocytic leukemia (CLL). However, resistance can emerge when tumor cells acquire mutations that abrogate drug binding or when BTK activates B-cell receptor (BCR) signaling by mechanisms independent of its kinase activity. In this study, we identified upregulation of PKCβ in samples from patients with CLL resistant to BTK inhibitors (BTKi) and characterized the PKCβ inhibitor MS-553. MS-553 reduced BCR and Wnt/β-catenin signaling, overcame stromal cell mediated protection, and synergized with venetoclax in CLL samples. MS-553 also retained the cytotoxicity and inhibition of both BCR and Wnt/β-catenin signaling in models (cell lines and primary samples) of covalent BTKi-resistant (C481S BTK) and noncovalent BTKi-resistant (T474I or L528W BTK) CLL. Furthermore, MS-553 delayed disease progression and prolonged survival in the Eμ-MTCP1 murine model of CLL. Collectively our results demonstrate that selective inhibition of PKCβ has the potential to overcome BTKi-resistant CLL. Significance: This study identified and characterized PKCβ as a therapeutic target in CLL, including CLL resistant to BTKis. Inhibition of PKCβ suppressed both BCR and Wnt/β-catenin signaling, delayed disease progression in vivo, overcame BTKi resistance mechanisms, and enhanced response to BCL-2 inhibition. See related commentary by Jebaraj and Stilgenbauer, p. 21

1 March 1993 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
RGR. Greek
R. Greek
PMP. Maurer
P. Maurer
MTMarc C Torjman
Marc C Torjman
HSH. Schieren
H. Schieren
JFJ. Finke
J. Finke
Jaime SeltzerJaime Seltzer
Jaime Seltzer



12 January 2026
Verified
Other
Open access
BGBritten K. Gordon
Britten K. Gordon
EMElizabeth M. Muhowski
Elizabeth M. Muhowski
JSJyotsana Singh
Jyotsana Singh
JRJanani Ravikrishnan
Janani Ravikrishnan
APArnau Peris-Cuesta
Arnau Peris-Cuesta
JWJennifer A. Woyach
Jennifer A. Woyach
Characteristics of CLL patients with dual-refractory disease